You might explore prescription GLP-1 drugs if: You might explore oral GLP-1 pathway support if: In either case: The GLP-1 supplement market is flooded
Ozempic may require additional attention in patients with diabetes who need monitoring for blood-sugar changes, diabetic retinopathy concerns, and medication interactions
Cardiovascular and Vascular Research Comprehensive Vascular Protection and Repair Research on component peptides examined effects in various cardiovascular scenarios with complementary mechanisms[17]: BPC-157: Improved healing in vascular anastomosis models and arrhythmia protection TB-500: Enhanced angiogenesis and collateral circulation development GHK-Cu: Support for endothelial function and vascular remodeling KPV: Potential to reduce vascular inflammation Combined approach supports vessel repair, new vessel formation, and inflammation control Studies demonstrated cardioprotective effects in ischemia-reperfusion models, with potential synergy between angiogenic promotion and inflammatory modulation
Tirzepatide: Dual GLP-1 and GIP Receptor Agonist Tirzepatide represents the next evolution in peptide therapy because it activates not just GLP-1 receptors but also GIP (glucose-dependent insulinotropic polypeptide) receptors
Rybelsus (semaglutide tablets) prescribing information
Compounded Two main pathways exist for prescription GLP-1 access: FDA-approved branded drugs (Ozempic, Wegovy, Mounjaro, Zepbound) dispensed by retail/mail-order pharmacies, and compounded semaglutide and tirzepatide from licensed 503A compounding pharmacies